Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria

详细信息    查看全文

• 作者：Walter Royal III (1)
  Mariana Cherner (2)
  Jean Carr (3)
  Abdulrazaq G. Habib (4)
  Abimbola Akomolafe (5)
  Alashl’e. Abimiku (3)
  Manhattan Charurat (3)
  John Farley (3)
  Akinwande Oluyemisi (6)
  Ibrahim Mamadu (6)
  Joyce Johnson (3)
  Ronald Ellis (2)
  J. Allen McCutchen (2)
  Igor Grant (2)
  William A. Blattner (3)
  
• 关键词：HIV ; 1 ; Cognitive impairment ; Nigeria ; Viral subtype ; IHDS
• 刊名：Journal of NeuroVirology
• 出版年：2012
• 出版时间：June 2012
• 年：2012
• 卷：18
• 期：3
• 页码：191-199
• 全文大小：230KB
• 参考文献：1. Abimiku AG (2009) Building laboratory infrastructure to support scale-up of HIV/AIDS treatment, care, and prevention: in-country experience. Am J Clin Pathol 131:875-86 f="http://dx.doi.org/10.1309/AJCPELMG6GX6RQSM">CrossRef
  2. Abimiku AG, Stern TL, Zwandor A, Markham PD, Calef C, Kyari S, Saxinger WC, Gallo RC, Robert-Guroff M, Reitz MS (1994) Subgroup G HIV type 1 isolates from Nigeria. AIDS Res Hum Retrovir 10:1581-583 f="http://dx.doi.org/10.1089/aid.1994.10.1581">CrossRef
  3. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-958 f="http://dx.doi.org/10.1126/science.272.5270.1955">CrossRef
  4. Anderson E, Zink W, Xiong H, Gendelman HE (2002) HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr 31(Suppl 2):S43–S54
  5. Anthonypillai C, Gibbs JE, Thomas SA (2006) The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res 3:1 f="http://dx.doi.org/10.1186/1743-8454-3-1">CrossRef
  6. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789-799 f="http://dx.doi.org/10.1212/01.WNL.0000287431.88658.8b">CrossRef
  7. Belec PL, Testa J, Vohito MD, Gresenguet G, Martin MI, Tabo A, Di Costanzo B, Georges AJ (1989) Neurologic and psychiatric manifestations of AIDS in Central African Republic. Bull Soc Pathol Exot Fil 82:297-07
  8. Berger JR, Moskowitz L, Fischl M, Kelley RE (1987) Neurologic disease as the presenting manifestation of acquired immunodeficiency syndrome. South Med J 80:683-86 f="http://dx.doi.org/10.1097/00007611-198706000-00004">CrossRef
  9. Burdo TH, Gartner S, Mauger D, Wigdahl B (2004) Region-specific distribution of human immunodeficiency virus type 1 long terminal repeats containing specific configurations of CCAAT/enhancer-binding protein site II in brains derived from demented and nondemented patients. J Neurovirol 10(Suppl 1):7-4
  10. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-66 f="http://dx.doi.org/10.1038/381661a0">CrossRef
  11. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ (1999) Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13:1249-253 f="http://dx.doi.org/10.1097/00002030-199907090-00015">CrossRef
  12. Eyzaguirre LM, Erasilova IB, Nadai Y, Saad MD, Kovtunenko NG, Gomatos PJ, Zeman VV, Botros BA, Sanchez JL, Birx DL, Earhart KC, Carr JK (2007) Genetic characterization of HIV-1 strains circulating in Kazakhstan. J Acquir Immune Defic Syndr 46:19-3 f="http://dx.doi.org/10.1097/01.qai.0000286598.00313.a6">CrossRef
  13. Felsenstein J (1995) Phylogeny inference package (PHYLIP)
  14. Foudraine NA, Hoetelmans RM, Lange JM, de Wolf F, van Benthem BH, Maas JJ, Keet IP, Portegies P (1998) Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine [see comments]. Lancet 351:1547-551 f="http://dx.doi.org/10.1016/S0140-6736(98)07333-4">CrossRef
  15. Foudraine NA, Jurriaans S, Weverling GJ, Burger DM, Hoetelmans RM, Roos MT, Maas J, Miedema F, Reiss P, Portegies P, de Wolf F, Lange JM (2001) Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial. Antivir Ther 6:55-2
  16. Ganasen KA, Fincham D, Smit J, Seedat S, Stein D (2008) Utility of the HIV dementia scale (HDS) in identifying HIV dementia in a South African sample. J Neurol Sci 269:62-4 f="http://dx.doi.org/10.1016/j.jns.2007.12.027">CrossRef
  17. Gartner S, Markovits P, Markovitz DM, Betts RF, Popovic M (1986) Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA 256:2365-371 f="http://dx.doi.org/10.1001/jama.1986.03380170081023">CrossRef
  18. Hall KS, Gao S, Emsley CL, Ogunniyi AO, Morgan O, Hendrie HC (2000) Community screening interview for dementia (CSI 'D'); performance in five disparate study sites. Int J Geriatr Psychiatry 15:521-31 f="http://dx.doi.org/10.1002/1099-1166(200006)15:6<521::AID-GPS182>3.0.CO;2-F">CrossRef
  19. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, Mackay CR, Sodroski J, Gabuzda D (1997) CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 385:645-49 f="http://dx.doi.org/10.1038/385645a0">CrossRef
  20. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3-6 f="http://dx.doi.org/10.1007/s13365-010-0006-1">CrossRef
  21. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, Yergey JA, Mouradian MM, Sadler AE, Keilp J, Rubinow D, Markey SP (1991) Quinolinic acid i cerebrospinal fluid and serum in HIV-1 infection: relationsyip to clinical and neurological status. Ann Neurol 29:202-09 f="http://dx.doi.org/10.1002/ana.410290215">CrossRef
  22. Howlett WP, Nkya WM, Mmuni KA, Missalek WR (1989) Neurological disorders in AIDS and HIV disease in the northern zone of Tanzania. AIDS 3:289-96 f="http://dx.doi.org/10.1097/00002030-198905000-00007">CrossRef
  23. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR (1991) Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71-4 f="http://dx.doi.org/10.1126/science.1905842">CrossRef
  24. Kanmogne GD, Kuate CT, Cysique LA, Fonsah JY, Eta S, Doh R, Njamnshi DM, Nchindap E, Franklin DR Jr, Ellis RJ, McCutchan JA, Binam F, Mbanya D, Heaton RK, Njamnshi AK (2010) HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurol 10:60 f="http://dx.doi.org/10.1186/1471-2377-10-60">CrossRef
  25. Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA (2000) Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob Agents Chemother 44:2173-175 f="http://dx.doi.org/10.1128/AAC.44.8.2173-2175.2000">CrossRef
  26. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65-0 f="http://dx.doi.org/10.1001/archneurol.2007.31">CrossRef
  27. Levy RM, Bredesen DE, Rosinblum ML (1985) Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 62:475-95 f="http://dx.doi.org/10.3171/jns.1985.62.4.0475">CrossRef
  28. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC (1999) Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73:152-60
  29. Lum H, Isichei C, Isichei-Wakili M, Redfield R (2007) Expansion of HIV-1 screening and anti-retroviral treatment programs in a resource-poor setting: results from a faith-based organization in Jos, Plateau State, Nigeria. Afr Health Sci 7:93-00
  30. McCutchan FE, Carr JK, Bajani M, Sanders-Buell E, Harry TO, Stoeckli TC, Robbins KE, Gashau W, Nasidi A, Janssens W, Kalish ML (1999) Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology 254:226-34 f="http://dx.doi.org/10.1006/viro.1998.9505">CrossRef
  31. Meltzer MS, Skillman DR, Gomatos PJ, Kalter DC, Gendelman HE (1990) Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu Rev Immunol 8:169-4 f="http://dx.doi.org/10.1146/annurev.iy.08.040190.001125">CrossRef
  32. Nath A (2002) Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 186(Suppl 2):S193–S198 f="http://dx.doi.org/10.1086/344528">CrossRef
  33. National Agency for the Control of Aids (2010) United Nations general assembly special session (UNGASS) Country Progress Report: Nigeria
  34. Njamnshi AK, Djientcheu VP, Fonsah JY, Yepnjio FN, Njamnshi DM, Muna WE (2008) The International HIV Dementia Scale is a useful screening tool for HIV-associated dementia/cognitive impairment in HIV-infected adults in Yaounde-Cameroon. J Acquir Immune Defic Syndr 49:393-97 f="http://dx.doi.org/10.1097/QAI.0b013e318183a9df">CrossRef
  35. Njamnshi AK, Bissek AC, Ongolo-Zogo P, Tabah EN, Lekoubou AZ, Yepnjio FN, Fonsah JY, Kuate CT, Angwafor SA, Dema F, Njamnshi DM, Kouanfack C, Djientcheu VP, Muna WF, Kanmogne GD (2009) Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaounde-Cameroon. J Neurol Sci 285:149-53 f="http://dx.doi.org/10.1016/j.jns.2009.06.043">CrossRef
  36. Odiase F, Ogunrin O, Ogunniyi A (2006) Effect of progression of disease on cognitive performance in HIV/AIDS. J Natl Med Assoc 98:1260-262
  37. Perriens JH, Mussa M, Luabeya MK, Kayembe K, Kapita B, Brown C, Piot P, Janssen R (1992) Neurological complications of HIV-1-seropositive internal medicine inpatients in Kinshasa, Zaire. J Acquir Immune Defic Syndr 5:333-40
  38. Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, Haapasalo H, Krohn K (1995) Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS 9:1001-008 f="http://dx.doi.org/10.1097/00002030-199509000-00004">CrossRef
  39. Riedel D, Ghate M, Nene M, Paranjape R, Mehendale S, Bollinger R, Sacktor N, McArthur J, Nath A (2006) Screening for human immunodeficiency virus (HIV) dementia in an HIV clade C-infected population in India. J Neurovirol 12:34-8 f="http://dx.doi.org/10.1080/13550280500516500">CrossRef
  40. Robertson K, Kopnisky K, Mielke J, Appiah K, Hall C, Price R, Kumwenda J, Kanyama C, Amod F, Marra C, Taylor T, Lalloo U, Jelsma J, Holding P, Boivin M, Birbeck G, Nakasujja N, Sanne I, Parsons TD, Parente A, Tucker K (2005) Assessment of neuroAIDS in Africa. J Neurovirol 11(Suppl 1):7-6
  41. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC (2001) HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990-998. Neurology 56:257-60 f="http://dx.doi.org/10.1212/WNL.56.2.257">CrossRef
  42. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136-42 f="http://dx.doi.org/10.1080/13550280290049615">CrossRef
  43. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, Robertson K, McArthur JC, Ronald A, Katabira E (2005) The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 19:1367-374
  44. Sacktor N, Nakasujja N, Skolasky R, Robertson K, Wong M, Musisi S, Ronald A, Katabira E (2006) Antiretroviral therapy improves cognitive impairment in HIV + individuals in sub-Saharan Africa. Neurology 67:311-14 f="http://dx.doi.org/10.1212/01.wnl.0000225183.74521.72">CrossRef
  45. Sacktor N, Nakasujja N, Skolasky RL, Rezapour M, Robertson K, Musisi S, Katabira E, Ronald A, Clifford DB, Laeyendecker O, Quinn TC (2009) HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 49:780-86 f="http://dx.doi.org/10.1086/605284">CrossRef
  46. Sebit MB (1995) Neuropsychiatric HIV-1 infection study: in Kenya and Zaire cross-sectional phase I and II. Cent Afr J Med 41:315-22
  47. Shieh JT, Albright AV, Sharron M, Gartner S, Strizki J, Doms RW, Gonzalez-Scarano F (1998) Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia. J Virol 72:4243-249
  48. Snider WD, Simpson DM, Nielsen S, Gold JW, Metroka CE, Posner JB (1983) Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 14:403-18 f="http://dx.doi.org/10.1002/ana.410140404">CrossRef
  49. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A (2009) Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 52:56-3 f="http://dx.doi.org/10.1097/QAI.0b013e3181af83d6">CrossRef
  50. Weniger BG, Takebe Y, Ou CY, Yamazaki S (1994) The molecular epidemiology of HIV in Asia. AIDS 8(Suppl 2):S13–S28
  51. Wesselingh SL, Power C, Glass JD, Tyor WR, McArthur JC, Farber JM, Griffin JW, Griffin DE (1993) Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 33:576-82 f="http://dx.doi.org/10.1002/ana.410330604">CrossRef
  52. Wong MH, Robertson K, Nakasujja N, Skolasky R, Musisi S, Katabira E, McArthur JC, Ronald A, Sacktor N (2007) Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 68:350-55 f="http://dx.doi.org/10.1212/01.wnl.0000252811.48891.6d">CrossRef
  
• 作者单位：Walter Royal III (1)
  Mariana Cherner (2)
  Jean Carr (3)
  Abdulrazaq G. Habib (4)
  Abimbola Akomolafe (5)
  Alashl’e. Abimiku (3)
  Manhattan Charurat (3)
  John Farley (3)
  Akinwande Oluyemisi (6)
  Ibrahim Mamadu (6)
  Joyce Johnson (3)
  Ronald Ellis (2)
  J. Allen McCutchen (2)
  Igor Grant (2)
  William A. Blattner (3)
  
  1. Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA
  2. HIV Neurobehavioral Research Center, The University of San Diego School of Medicine, La Jolla, CA, USA
  3. Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
  4. Institute of Human Virology-Nigeria, University of Maryland School of Medicine, Abuja, Nigeria
  5. Department of Medicine, Morehouse School of Medicine, Atlanta, GA, USA
  6. Institute of Human Virology-Nigeria, University of Maryland School of Medicine, Abuja, Nigeria
  
• ISSN：1538-2443

文摘

In Nigeria, the incidence and prevalence of human immunodeficiency virus (HIV)-related neurocognitive impairment (NCI) are unknown and there currently exists little information related to the viral correlates rates of NCI. Therefore, studies were performed to examine the potential utility of applying an established neuropsychological (NP) screening battery and detailed NP testing to detect NCI and correlations with functional impairment and the presence of specific viral signatures among infected subjects. A total of 60 HIV-1 seropositive antiretroviral-naive individuals and 56 seronegative control subjects were administered the International HIV Dementia Scale (IHDS) and assessed for functional impairment using the Karnofsky performance status scale. Fifteen HIV-infected patients and 11 controls were also administered a detailed NP battery. Blood samples from eight infected subjects, three with evidence of NCI, were obtained for molecular analysis of HIV-1 strain. Unadjusted scores on the IHDS showed that, using a recommended total score cutoff of 10, 28.8?% of the HIV-1 seropositive and 16.0?% of seropositive individuals scored abnormally. Results from testing using the full NP battery showed that, overall, the HIV seropositive group performed worse than the seronegative group, with effect sizes spanning from small (0.25 on the trail making test A) to large (0.82 on action fluency), and an average effect size across the battery of 0.45, which approaches that which has been recorded in other international settings. Sequencing of partial pol amplicons from viral isolates revealed that two of three patients with NCI were infected with subtype G virus and 1 with the circulating recombinant form (CRF)02_AG; all four individuals without NCI were infected with CRF_02AG. These studies demonstrate the utility of the IHDS in identifying cognitive impairment among HIV infected individuals in Nigeria. Future studies aimed at examining the burden of NCI among the population of individuals with HIV-1 infection in Nigeria and which assess the virologic correlates will contribute to the evolving understanding of the pathogenetic factors that underlie this disorder.